Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Disease area: Airway diseases, Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Spencer, M. McKean, C. O‘Brien, A. Kirk, M. Samantha (United Kingdom). The oral corticosteroid sparing effect of omalizumab in paediatric patients with severe chronic asthma. Eur Respir J 2010; 36: Suppl. 54, 2635

Member's Comments

No comment yet.

Related content which might interest you: Oral corticosteroids in the treatment of exacerbation of severe asthma Source: Virtual Congress 2020 – Exhaled biomarkers of asthma and the asthma burden Year: 2020 Patients with moderate asthma symptoms may benefit from short-term inhaled corticosteroid monotherapy Source: Eur Respir J 2007; 30: Suppl. 51, 615s Year: 2007 Effect of dupilumab on oral corticosteroid use in severe asthma patients with improving lung function Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma Year: 2020 Oral montelukast in patients with acute severe asthma Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma Year: 2007 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 The use of omalizumab in the management of severe chronic paediatric asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008 Decreasing dose protocol for omalizumab treatment in oral corticosteroid allergic asthma patients Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011 The oral corticosteroid sparing effect of omalizumab in patients with severe chronic asthma: Is there a difference when you become 12 years old? Source: Annual Congress 2011 - Treating childhood asthma Year: 2011 Impact of omalizumab in patients with severe asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 An economic evaluation of adding inhaled corticosteroids to systemic corticosteroids for treating acute asthma exacerbations Source: International Congress 2019 – Severe acute asthma and troublesome wheezing Year: 2019 Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids Source: Breathe 2010; 6: 365 Year: 2010 Discontinuation of inhaled corticosteroid treatment in patients with COPD diagnosed in general practice Source: Eur Respir J 2002; 20: Suppl. 38, 212s Year: 2002 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma Source: International Congress 2017 – Asthma management Year: 2017 Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007 Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 Efficacy of inhaled heparin is effective in the treatment of acute exacerbation of asthma Source: Annual Congress 2007 - New drugs for asthma Year: 2007 Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 Rescue-free days in patients with mild persistent asthma receiving montelukast sodium or an inhaled corticosteroid Source: Eur Respir J 2002; 20: Suppl. 38, 113s Year: 2002 Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009